Home › NCT07400965

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Signs of Demodex blepharitis in at least one eye
* Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye

Exclusion Criteria:

* Presence of eczema or dermatitis in the ocular region of either eye
* Use of lid hygiene products within 14 days of Screening
* Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
* Women who are pregnant, planning a pregnancy, or nursing
* Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial

About the study

This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.

What is being tested

• GLK-321 low dose BID (drug)
• GLK-321 mid dose BID (drug)
• GLK-321 high dose BID (drug)
• GLK-321 high dose QD (drug)
• Placebo BID (drug)

Sponsor: Glaukos Corporation · Participants: 250 · Started: Dec 5, 2025

Contact the study team

• Study Manager · Phone: 949-739-8749

Official record on ClinicalTrials.gov — NCT07400965

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.